CSMS Message: 18-000221

FDA continues to receive multiple PG24 records per line. Per FDA's Supplemental Guide, https://www.cbp.gov/document/guidance/fda-supplemental-guide-release-16, only one PG24 Remarks record is allowed per PG02; IE only one PG24 is allowed per FDA line and remarks type must be “GEN”. FDA has received many entries which contain multiple PG24 records per FDA line. When multiple PG24 Remarks records are received per line, FDA is only able to process one record. Failure to follow Supplemental Guide instructions will prevent FDA field staff from receiving remarks entered by the filer and could cause delays in review or prevent processing.

In addition, FDA is receiving transmissions where the PG24 record is not in the correct location; IE not a child of the PG02.

Beginning April 26, 2018, if FDA receives multiple PG24 records on an FDA line and/or the PG24 record is not under PG02 or does not have the remarks type “GEN”, the entry will be rejected.

For technical ACE inquiries, contact FDA ACE Support at ACE_Support@fda.hhs.gov or 877-345-1101, from 6:00 AM -10:00 PM Eastern, 7 days a week.